Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy - Slideshow (NASDAQ:SRPT) 2026-01-27
Sarepta Therapeutics(US:SRPT) Seeking Alpha·2026-01-27 17:02技术访问问题 - 用户需在浏览器中启用Javascript和cookies以正常访问内容[1] - 启用广告拦截器可能导致访问受阻 建议用户禁用广告拦截器并刷新页面[1]